• Contact

  • Newsletter

  • About us

  • Delivery options

  • Prospero Book Market Podcast

  • Controlled Drug Delivery of Hydrophobic Drug: Development and Evaluation of Oral Controlled Drug Delivery of BCS Class-II Drug Glipizide

    Controlled Drug Delivery of Hydrophobic Drug by Jagtap, Rajesh; Jagtap, Sneha; Chavan, Sandeep;

    Development and Evaluation of Oral Controlled Drug Delivery of BCS Class-II Drug Glipizide

      • GET 5% OFF

      • The discount is only available for 'Alert of Favourite Topics' newsletter recipients.
      • Publisher's listprice EUR 54.90
      • The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.

        22 769 Ft (21 685 Ft + 5% VAT)
      • Discount 5% (cc. 1 138 Ft off)
      • Discounted price 21 631 Ft (20 601 Ft + 5% VAT)

    22 769 Ft

    db

    Availability

    printed on demand

    Why don't you give exact delivery time?

    Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.

    Product details:

    • Publisher LAP Lambert Academic Publishing
    • Date of Publication 1 January 2020

    • ISBN 9786202518062
    • Binding Paperback
    • No. of pages96 pages
    • Size 220x150 mm
    • Language English
    • 25

    Categories

    Long description:

    Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. It is practically water-insoluble, thus it belongs to class-II of Biopharmaceutical Classification System (BCS). Glipizide has a relatively short elimination half-life (2-4 h), thereby requiring twice daily dosing in large number of patients, which often leads to non-compliance. Thus, there is a strong clinical need and market potential for a dosage form that will deliver glipizide in a controlled manner to a patient needing this therapy, thereby resulting in a better patient compliance. The aim of present investigation was to enhance the solubility by using beta-cyclodextrin binary complexation and impart a controlled release in a single formulation in order to reduce dosing frequency.

    More